Literature DB >> 20638021

Hepatitis B virology for clinicians.

Edward C Doo1, Marc G Ghany.   

Abstract

A basic understanding of the molecular events involved in the hepatitis B virus (HBV) life cycle is essential to better appreciate the natural history and atypical presentations of the disease and to develop individual management plans based on readily available virologic tests. With the improved knowledge gained from studying the molecular biology of HBV, novel approaches to inhibition of viral replication are being explored, such as viral entry inhibitors, nucleocapsid inhibitors, and inhibitors of viral assembly. However, the ultimate goal of therapy is to identify strategies to eliminate covalently closed circular DNA from infected hepatocytes. This article serves to introduce the clinically relevant aspects of the HBV life cycle as they pertain to patient management. 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20638021      PMCID: PMC7464571          DOI: 10.1016/j.cld.2010.05.001

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  51 in total

1.  Viral clearance without destruction of infected cells during acute HBV infection.

Authors:  L G Guidotti; R Rochford; J Chung; M Shapiro; R Purcell; F V Chisari
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

2.  Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.

Authors:  Karsten Wursthorn; Marc Lutgehetmann; Maura Dandri; Tassilo Volz; Peter Buggisch; Bernhard Zollner; Thomas Longerich; Peter Schirmacher; Frauke Metzler; Myrga Zankel; Conrad Fischer; Graeme Currie; Carol Brosgart; Joerg Petersen
Journal:  Hepatology       Date:  2006-09       Impact factor: 17.425

3.  Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes.

Authors:  Dieter Glebe; Stephan Urban; Eva V Knoop; Nilgün Cag; Peter Krass; Stefanie Grün; Aiste Bulavaite; Kestutis Sasnauskas; Wolfram H Gerlich
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

4.  Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/threonine kinases.

Authors:  J C Cross; P Wen; W J Rutter
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-01       Impact factor: 11.205

5.  The relationship of hepatitis B e antigen, DNA polymerase activity, and titer of hepatitis B surface antigen with ongoing liver injury in chronic hepatitis B virus infection.

Authors:  R Perrillo; C Campbell; W Wellinghoff; L Gelb
Journal:  Am J Gastroenterol       Date:  1982-07       Impact factor: 10.864

6.  In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway.

Authors:  T T Wu; L Coates; C E Aldrich; J Summers; W S Mason
Journal:  Virology       Date:  1990-03       Impact factor: 3.616

7.  Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.

Authors:  Joerg Petersen; Maura Dandri; Walter Mier; Marc Lütgehetmann; Tassilo Volz; Fritz von Weizsäcker; Uwe Haberkorn; Lutz Fischer; Joerg-Matthias Pollok; Berit Erbes; Stefan Seitz; Stephan Urban
Journal:  Nat Biotechnol       Date:  2008-02-24       Impact factor: 54.908

8.  Lamivudine therapy of WHV-infected woodchucks.

Authors:  W S Mason; J Cullen; G Moraleda; J Saputelli; C E Aldrich; D S Miller; B Tennant; L Frick; D Averett; L D Condreay; A R Jilbert
Journal:  Virology       Date:  1998-05-25       Impact factor: 3.616

Review 9.  Does RNA interference provide new hope for control of chronic hepatitis B infection?

Authors:  Rachel Wilson; Damian Purcell; Hans J Netter; Peter A Revill
Journal:  Antivir Ther       Date:  2009

10.  The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes.

Authors:  J E Newbold; H Xin; M Tencza; G Sherman; J Dean; S Bowden; S Locarnini
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

View more
  8 in total

1.  Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation.

Authors:  Nagraj Mani; Andrew G Cole; Janet R Phelps; Andrzej Ardzinski; Kyle D Cobarrubias; Andrea Cuconati; Bruce D Dorsey; Ellen Evangelista; Kristi Fan; Fang Guo; Haitao Guo; Ju-Tao Guo; Troy O Harasym; Salam Kadhim; Steven G Kultgen; Amy C H Lee; Alice H L Li; Quanxin Long; Sara A Majeski; Richeng Mao; Kevin D McClintock; Stephen P Reid; Rene Rijnbrand; Nicholas M Snead; Holly M Micolochick Steuer; Kim Stever; Sunny Tang; Xiaohe Wang; Qiong Zhao; Michael J Sofia
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 2.  Emerging antivirals for the treatment of hepatitis B.

Authors:  Xue-Yan Wang; Hong-Song Chen
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

3.  DNA Polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA.

Authors:  Liudi Tang; Muhammad Sheraz; Michael McGrane; Jinhong Chang; Ju-Tao Guo
Journal:  PLoS Pathog       Date:  2019-04-26       Impact factor: 6.823

Review 4.  HBV cccDNA and Its Potential as a Therapeutic Target.

Authors:  Anjing Zhu; Xinzhong Liao; Shuang Li; Hang Zhao; Limin Chen; Min Xu; Xiaoqiong Duan
Journal:  J Clin Transl Hepatol       Date:  2019-07-31

5.  The prevalence of HBsAg, knowledge and practice of hepatitis B prevention among pregnant women in the Limbe and Muyuka Health Districts of the South West region of Cameroon: a three-year retrospective study.

Authors:  Esum Mathias Eyong; Brenda Mbouamba Yankam; Esemu Seraphine; Che Henry Ngwa; Ngwayu Claude Nkfusai; Cho Sebastine Anye; Gilbert Karngong Nfor; Samuel Nambile Cumber
Journal:  Pan Afr Med J       Date:  2019-03-15

6.  Synthesis, characterization and biological activity of a niobium-substituted-heteropolytungstate on hepatitis B virus.

Authors:  Hong Zhang; Yanfei Qi; Yanhua Ding; Juan Wang; Qingmei Li; Jingzhou Zhang; Yanfang Jiang; Xiumei Chi; Juan Li; Junqi Niu
Journal:  Bioorg Med Chem Lett       Date:  2012-01-02       Impact factor: 2.823

7.  Seroclearance of Hbsag in Chronic Hepatitis B Virus Patients on Lamivudine Therapy: A 10 Year Experience.

Authors:  Shahnaz Sali; Muayad A Merza; Sina Saadat; Nazik H Mustafa; Farzam Queiky; Davood Yadegarynia
Journal:  Glob J Health Sci       Date:  2015-04-02

8.  Delivery of cell-penetrating peptide-peptide nucleic acid conjugates by assembly on an oligonucleotide scaffold.

Authors:  Xing-Liang Zhao; Bi-Cheng Chen; Jin-Chao Han; Lai Wei; Xiao-Ben Pan
Journal:  Sci Rep       Date:  2015-11-27       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.